Antiviral agents target specific steps in the viral life cycle to inhibit replication and reduce the burden of viral infections. Unlike antibiotics, which can often eradicate bacteria, antiviral drugs typically suppress viral replication while relying on the host immune system to clear the infection. The development of antiviral therapy has transformed the prognosis of HIV, hepatitis B and C, and herpesvirus infections from life-threatening diseases to manageable chronic conditions.
What Are Antiviral Agents?
Viruses are obligate intracellular parasites that hijack host cellular machinery for replication. The viral life cycle includes attachment, entry, uncoating, genome replication, protein synthesis, assembly, and release. Each step represents a potential target for antiviral intervention. The challenge of antiviral drug development lies in achieving selectivity for viral targets while sparing host cell functions, a goal facilitated by differences between viral and mammalian enzymes.
Mechanism of Action
Neuraminidase inhibitors such as oseltamivir and zanamivir block the influenza neuraminidase enzyme, which is required for the release of newly formed viral particles from infected cells. By preventing viral spread within the respiratory tract, these drugs reduce the duration and severity of influenza symptoms when started within forty-eight hours of symptom onset.
Nucleoside reverse transcriptase inhibitors such as zidovudine, tenofovir, and emtricitabine are prodrugs that undergo intracellular phosphorylation to active triphosphate forms. These compete with natural nucleotides for incorporation into viral DNA by reverse transcriptase, where they act as chain terminators because they lack the 3-hydroxyl group required for further DNA chain elongation. NRTIs are fundamental components of antiretroviral therapy for HIV.
Protease inhibitors such as ritonavir, atazanavir, and darunavir inhibit the viral protease enzyme that cleaves viral polyproteins into functional proteins during virion maturation. Protease inhibitors are used in both HIV and hepatitis C virus treatment. Ritonavir is a potent CYP3A4 inhibitor used at low doses to pharmacokinetically boost other protease inhibitors, increasing their plasma concentrations and dosing intervals.
Polymerase inhibitors target viral DNA or RNA polymerases essential for genome replication. Acyclovir, after activation by viral thymidine kinase, inhibits herpes simplex virus DNA polymerase. Remdesivir, a nucleotide analog, inhibits the RNA-dependent RNA polymerase of SARS-CoV-2 and other RNA viruses. Sofosbuvir targets the hepatitis C virus NS5B polymerase and has revolutionized hepatitis C treatment with cure rates exceeding ninety-five percent.
Therapeutic Uses
Antiviral agents are used for treatment and prophylaxis of influenza, herpes simplex and varicella-zoster infections, cytomegalovirus in immunocompromised patients, HIV, hepatitis B, and hepatitis C. The development of direct-acting antiviral combinations for hepatitis C has made cure possible for most patients. Antiretroviral therapy for HIV suppresses viral replication indefinitely, preventing progression to AIDS and reducing transmission.
Adverse Effects
Adverse effects vary by drug class. NRTIs can cause mitochondrial toxicity manifesting as lactic acidosis, hepatic steatosis, and peripheral neuropathy. Protease inhibitors cause gastrointestinal intolerance, hyperlipidemia, and insulin resistance. Acyclovir can cause nephrotoxicity when given intravenously. Drug interactions are common, particularly with protease inhibitors that inhibit or induce CYP450 enzymes.
Contraindications
Dose adjustments are required for renal impairment for many antiviral agents. Specific contraindications include tenofovir in patients with severe renal impairment and certain protease inhibitors in patients with severe hepatic impairment. Resistance testing guides drug selection in HIV and hepatitis C therapy.
Conclusion
Antiviral therapy has progressed from a few agents with modest efficacy to a broad armamentarium capable of suppressing chronic viral infections and curing others. The rapid development of effective therapies during the COVID-19 pandemic demonstrated the potential of antiviral drug development when resources are mobilized against emerging viral threats.
